Category survey

Structural study of multiple homologous epitopes present on the molecule of intrinsically disordered protein tau Investments < €500k Slovakia 2016    

Tractography and magnetic resonance spectroscopy in animal models looking for new biomarkers of early stages of Alzheimer-type dementia Investments < €500k Slovakia 2016    

Evaluation of non-explosive symptoms in people with Parkinson’s disease treated with deep stimulation of the hypothalamic nucleus Investments < €500k Poland 2016    

Evaluation of the profile and disorders of emotional processes in patients with atrial fibrillation, Alzheimer’s disease and frontal-temporal dementia Investments < €500k Poland 2016    

Disorders of sacacia refixation in people with neurodegenerative disease Investments < €500k Poland 2016    

Search for new multifunction ligands affecting neurodegenerative processes (behavioral and metabolic tests, in vivo) Investments < €500k Poland 2016    

New non-myomaide treatment of cognitive disorders (in vivo) Investments < €500k Poland 2016    

Pharmacological studies of new benzisoxazolopropylpyrrolidine derivatives as multifunctional ligands with potential prokaryotic and antipsychotic properties (in vivo, animal models) Investments < €500k Poland 2016    

Studies on benzylic derivatives of xanthines with expected MAO-B inhibitory activity and adenosine A1 and A2A receptors as compounds Investments < €500k Poland 2016    

Study on the analysis of N-glycosylation changes of glycoproteins and the role of glycosylation of protein quality control mechanism in cellular disease model Investments < €500k Poland 2016    

The calcium binding S100B protein as a modulator of amyloid β aggregation and a potential therapeutic target in Alzheimer’s disease Investments < €500k Portugal 2016    

Dysarthria in Parkinson’s disease: Lusophony vs. Francophony comparison Investments < €500k Portugal 2016    

Modulating Ire1 to prevent Parkinson’ Disease Investments < €500k Portugal 2016    

Targeting the glycation defenses as a protective strategy for Parkinson’s disease Investments < €500k Portugal 2016    

Alzheimer3D: Trifunctional Conjugates for the Selective Drug Delivery in Alzheimer’s Disease Investments < €500k Portugal 2016    

The role of intracellular trafficking in Alzheimer’s disease Investments < €500k Portugal 2016    

Blood based early and predictive diagnostics of Alzheimer’s dementia Investments < €500k Portugal 2016    

Targeting huntingtin proteostasis and mitochondria to prevent neuronal dysfunction in Huntington’s disease Investments < €500k Portugal 2016    

Whole-exome sequencing of discordant and concordant affected sib pairs in spinocerebellar ataxia type 3 (SCA3): a tool to identify novel modifier genes and highlight disrupted molecular pathways. Investments < €500k Portugal 2016    

Neurodegeneration and Brain Diseases: A new instrumental approach of analysis and development of pharmaceutical formulations Investments < €500k Romania 2016    

Voltage gated sodium channel modulation of microglia activity in Alzheimer’s disease (NCmicroAD) Investments < €500k Romania 2016    

Effects of 6-hydroxy-nicotine on chlorisondamine-induced oxidative stress and neurotoxicity: relevance for Alzheimer’s disease Investments < €500k Romania 2016    

Spatial orientation in patients with cognitive impairment and Alzheimer’s disease Investments < €500k Norway 2016    

Impact of base excision repair on epigenetics in brain; Implications for neurodegeneration Investments < €500k Norway 2016    

Deep brain stimulation for disabling action tremor: a controlled comparison of two different targets Investments < €500k Norway 2016    

Brain changes associated with dementia and mild cognitive impairment after stroke Investments < €500k Norway 2016    

Care transitions and delirium in nursing home residents Investments < €500k Norway 2016    

ABC-AD: ABC transporters as early diagnostics and treatment marker for neurodegenerative dementias – towards a personalised medicine in dementia Investments < €500k Norway 2016    

Imaging the origins of dementia: vascular, grey and white matters Investments < €500k Norway 2016    

Cardiovascular Health and Progression of Alzheimer´s disease (VAS-PAD) Investments < €500k Norway 2016    

Effects of an exercise program for nursing home patients with dementia Investments < €500k Norway 2016    

Gait in elderly with Parkinson´s disease – Long term effects of highly challenging balance training program Investments < €500k Norway 2016    

The Incidence and Prognosis of Dementia related to Drug use in out-patients with cognitive impairments (the IPoD-D-Study). Investments < €500k Norway 2016    

User participation for elderly persons with dementia living at home Investments < €500k Norway 2016    

Importance of low-grade inflammation in patients with cognitive impairment due to AD and stroke Investments < €500k Norway 2016    

Mapping the epigenetics of Lewy body dementias Investments < €500k Norway 2016    

Myelinating oligodendrocytes as a therapeutic target for Alzheimer’s Disease Investments < €500k Norway 2016    

Assessment of brain degeneration in relationship to psychomotor and cognitive functions in MCI and mild Alzheimer’s disease Investments < €500k Norway 2016    

The utility of VILIP-1 in the diagnosis of neurodegenerative diseases. Investments < €500k Poland 2016    

The usefulness of CSF YKL-40 measurements in the diagnosis of patients with neurodegenerative diaseases. Investments < €500k Poland 2016    

CSF YKL-40 as a potential biomarker of Alzheimer’s disease. Investments < €500k Poland 2016    

Genetic variability and efficacy of drugs used to treat Parkinson’s disease (NGS sequencing) Investments < €500k Poland 2016    

Patient derived iPS cells for investigating pathogenetic mechanisms of brain diseases that cause movement disorders Investments < €500k Norway 2016    

Efficacy of Pain Treatment on Depression in Patients with Dementia. A Randomized Clinical Trial of Efficacy Investments < €500k Norway 2016    

Acceleration of Parkinson pathogenesis by chronic low-dose rate gamma exposure – OSTINATO Investments < €500k Norway 2016    

Ostinato – Acceleration of Parkinson pathogenesis by chronic low-dose rate gamma exposure Investments < €500k Norway 2016    

QUONDAM: Quantitative analysis of naturally produced speech and language to improve diagnosis and monitoring of dementia Investments < €500k Norway 2016    

Decision Support System for Patient-Driven Monitoring Of Cognitive Decline through Computer Aided Personal Support for Cognitive Resources Investments < €500k Norway 2016    

Mitochondrial dysfunction in the pathogenesis of Parkinson’s disease: elucidating disease mechanisms and identifying therapeutic targets Investments < €500k Norway 2016    

Early Onset Dementia in Parkinson’s Disease: Molecular Mechanisms and Biomarker Discovery Investments < €500k Norway 2016